A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

被引：0
|
作者：
Figueiredo, Amarilis [1 ]
Atkins, Harold [1 ,2 ,3 ,4 ]
Mallick, Ranjeeta [5 ,6 ]
Kekre, Natasha [1 ,2 ,3 ,4 ]
Kew, Andrea [2 ,3 ,4 ]
McCurdy, Arleigh [1 ,3 ,4 ]
机构：
[1] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[2] Ottawa Hosp, Div Hematol, Ottawa, ON, Canada
[3] Ottawa Hosp, Dept Med, Ottawa, ON, Canada
[4] Univ Ottawa, Ottawa, ON, Canada
[5] Univ Ottawa, Sch Epidemiol, Publ Hlth & Prevent Med, Ottawa, ON, Canada
[6] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.4519.4519
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4519
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Kazuhito Suzuki
    Nobuhiro Tsukada
    Noriko Nishimura
    Yasuyuki Nagata
    Kiyoshi Okazuka
    Yuko Mishima
    Masahiro Yokoyama
    Kaichi Nishiwaki
    Tadao Ishida
    Shingo Yano
    Yasuhito Terui
    Kenshi Suzuki
    International Journal of Hematology, 2020, 111 : 103 - 111
  • [32] Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
    Rosinol, Laura
    Hebraud, Benjamin
    Oriol, Albert
    Colin, Anne-Laurene
    Tamayo, Rafael Rios
    Hulin, Cyrille
    Blanchard, Maria Jesus
    Caillot, Denis
    Sureda, Anna
    Hernandez, Miguel Teodoro
    Arnulf, Bertrand
    Mateos, Maria-Victoria
    Macro, Margaret
    San-Miguel, Jesus
    Belhadj, Karim
    Lahuerta, Juan Jose
    Garelik, M. Brigid
    Blade, Joan
    Moreau, Philippe
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment
    Saeed, Nabiha
    Khan, Zurrya
    Jehanzeb, Hamzah
    Shaikh, Taha
    Shaikh, Usman
    Adil, Salman N.
    Madni, Varisha
    Fatima, Hania
    Abiha, Umm E.
    Ali, Natasha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [34] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis
    Nishimura, Noriko
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nagata, Yasuyuki
    Okaduka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E214 - E215
  • [35] Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
    Uttervall, Katarina
    Bruchfeld, Johanna Borg
    Gran, Charlotte
    Walinder, Goran
    Mansson, Robert
    Lund, Johan
    Gahrton, Gosta
    Alici, Evren
    Nahi, Hareth
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (03) : 247 - 254
  • [36] Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
    Yimer, Habte
    Melear, Ason
    Faber, Edward
    Bensinger, William, I
    Burke, John M.
    Narang, Mohit
    Stevens, Don
    Gunawardena, Sriya
    Lutska, Yana
    Qi, Keqin
    Ukropec, Jon
    Qi, Ming
    Lin, Thomas S.
    Rifkin, Robert M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 492 - 502
  • [37] Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
    Zafar, Mir Sadaqat Hassan
    Khan, Afaq Ahmed
    Aggarwal, Shyam
    Bhargava, Manorama
    SOUTH ASIAN JOURNAL OF CANCER, 2018, 7 (01) : 58 - 60
  • [38] MAINTENANCE THERAPY WITH BORTEZOMIB/DEXAMETHASONE IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS CARRYING HIGH RISK FEATURES
    Mancuso, K.
    Tacchetti, P.
    Pantani, L.
    Rocchi, S.
    Rizzello, I.
    Caratozzolo, I.
    De Cicco, G.
    Fusco, A.
    Testoni, N.
    Terragna, C.
    Marzocchi, G.
    Martello, M.
    Borsi, E.
    Dozza, L.
    Zamagni, E.
    Cavo, M.
    HAEMATOLOGICA, 2019, 104 : 50 - 50
  • [39] BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE IS A GOOD INDUCTION TREATMENT FOR YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Lakhwani, S.
    Notario, C.
    de Bonis, C.
    Brena, J.
    Raya, J. M.
    Sanchez-Quintana, A.
    Rios-Rull, P.
    Trujillo-Gonzalez, M.
    Hernandez, M. T.
    HAEMATOLOGICA, 2014, 99 : 657 - 657
  • [40] Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma
    Jimenez-Zepeda, Victor H.
    Venner, Christopher P.
    Belch, Andrew
    Sandhu, Irwindeep
    Nikitina, Tatiana
    Hewitt, Joanne D.
    Duggan, Peter
    Neri, Paola
    Rashid-Kolvear, Fariborz
    Bahlis, Nizar J.
    BLOOD, 2015, 126 (23)
12345